Florida / New York

Ph: 561.316.3330

A Publication for the Practicing Medical Specialist, Industry Executive & Investor

Medical Device News Magazine is a digital Publication Founded in 2008, and proudly located in the United States

Medical Device News Magazine has established itself as one of the foremost and most trusted sources of comprehensive updates and insights within the medical device and biotech industries. Our publication is committed to delivering timely and relevant information, making it a go-to resource for professionals and enthusiasts alike.

Medical Device News Magazine is easily accessible to readers 24/7/365, allowing you to stay informed at your convenience, and it presents content that is a fast and engaging read. We take pride in offering valuable insights in a format that can be consumed quickly, ensuring that our audience stays ahead of the curve.

Furthermore, if you are interested in expanding your reach and visibility within this dynamic field, we encourage you to inquire about advertising opportunities with us.

"Medical Device and Biotechnology Sector News: Essential Key Insights and Noteworthy Developments that are Shaping the Future"

YolTech Therapeutics Granted FDA Orphan Drug and Rare Pediatric Disease Designations for YOLT-203 to Treat Primary Hyperoxaluria Type 1

After reviewing YolTech Therapeutics submission, the FDA determined that the therapy is not only appropriate for primary hyperoxaluria type 1 (PH1), but also applicable to the broader category of primary hyperoxaluria (PH). As a result, the designations were granted for PH, reflecting the expanded scope of the therapy’s potential impact. These dual designations underscore the transformative potential of YOLT-203 to address this rare and life-threatening genetic disorder.

Intensity Therapeutics Presents INT230-6 Phase 1/2 Data in Sarcoma and an Overview of its Ongoing Global Randomized Phase 3 Sarcoma Trial (“INVINCIBLE-3 Study”) in a Late-Breaking Session at the 2024 Annual Connective Tissue Oncology Society Meeting (CTOS)

Phase 1/2 data showed a median overall survival (“mOS”) of 21.3 months versus a synthetic control of 6.7 months, an increase in T-cell activation, and favorable safety profile for patients receiving INT230-6 alone notes Intensity Therapeutics.

Comprehensive Insights into Medical Device & Biotechnology Company Mergers, Acquisitions & Funding

Industry Expert Byline

FDA Medical Device Updates

Our Experts - Byline Articles

Advancements in Imaging

Invenio Imaging Announces Clinical Research Collaboration Agreement

“In this important clinical study, we will develop a novel image analysis algorithm based on machine learning to provide physicians with real-time feedback determining whether a biopsy sample contains cancer”, says Chris Freudiger, PhD, Co-Founder and CTO of Invenio Imaging.

Hospitals In the News

Medical Device and Biotechnology Executives: Innovative Professionals on the Move and Making Waves in the Industry

Non-Profit News

Healthcare - Understanding the Business Side of the Industry and Its Implications

Physician Answering Services

24/7 Coverage: How Physician Answering Services Are Changing the Game

Physicians find themselves juggling between patient appointments, emergencies, and the need to maintain a work-life balance. That’s where physician answering services step in, transforming the game by providing 24/7 coverage. Let’s delve into how these services are making a significant impact.

Healthcare Careers and Opportunities

In the Evolving Medical Field

Nurses Corner

Articles Designed to Inspire and Guide You Toward Achieving Excellence and Success in All Your Endeavors.